Ameritas Investment Partners, Inc. - APELLIS PHARMACEUTICALS INC ownership

APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 185 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.3%.

Quarter-by-quarter ownership
Ameritas Investment Partners, Inc. ownership history of APELLIS PHARMACEUTICALS INC
ValueSharesWeighting
Q1 2023$487,181
+30.9%
7,386
+0.4%
0.02%
+26.7%
Q4 2022$372,135
-25.9%
7,3530.0%0.02%
-31.8%
Q3 2022$502,000
+63.0%
7,353
+7.8%
0.02%
+69.2%
Q2 2022$308,000
-0.3%
6,819
+12.0%
0.01%
+18.2%
Q1 2022$309,000
+17.0%
6,090
+9.1%
0.01%
+22.2%
Q4 2021$264,000
+59.0%
5,580
+10.9%
0.01%
+50.0%
Q3 2021$166,000
-47.8%
5,0300.0%0.01%
-45.5%
Q2 2021$318,000
+47.2%
5,0300.0%0.01%
+37.5%
Q1 2021$216,000
-25.0%
5,0300.0%0.01%
-38.5%
Q4 2020$288,000
+80.0%
5,030
-5.2%
0.01%
+85.7%
Q3 2020$160,000
-7.5%
5,3050.0%0.01%
-12.5%
Q2 2020$173,000
+29.1%
5,305
+5.8%
0.01%0.0%
Q1 2020$134,000
+5.5%
5,014
+21.1%
0.01%
+33.3%
Q4 2019$127,000
+27.0%
4,1400.0%0.01%
+20.0%
Q3 2019$100,000
-4.8%
4,1400.0%0.01%0.0%
Q2 2019$105,000
+75.0%
4,140
+34.0%
0.01%
+66.7%
Q1 2019$60,000
+46.3%
3,0890.0%0.00%
+50.0%
Q4 2018$41,000
-25.5%
3,0890.0%0.00%
-33.3%
Q3 2018$55,000
-19.1%
3,0890.0%0.00%0.0%
Q2 2018$68,000
+240.0%
3,089
+235.8%
0.00%
+200.0%
Q1 2018$20,0000.0%9200.0%0.00%0.0%
Q4 2017$20,0009200.00%
Other shareholders
APELLIS PHARMACEUTICALS INC shareholders Q3 2021
NameSharesValueWeighting ↓
Octagon Capital Advisors LP 2,618,300$238,527,13033.19%
ACUTA CAPITAL PARTNERS, LLC 297,596$27,110,99618.37%
Avoro Capital Advisors LLC 11,111,111$1,012,222,21213.73%
EcoR1 Capital, LLC 5,451,647$496,645,04212.17%
Logos Global Management LP 625,000$56,937,5007.74%
Finepoint Capital LP 241,690$22,017,9597.62%
Cormorant Asset Management, LP 1,310,000$119,341,0006.68%
Boxer Capital, LLC 1,576,000$143,5746.66%
Saturn V Capital Management LP 107,406$9,784,6875.43%
Ghost Tree Capital, LLC 180,000$16,398,0005.41%
View complete list of APELLIS PHARMACEUTICALS INC shareholders